Abeona Therapeutics Stock (NASDAQ:ABEO)
Previous Close
$5.33
52W Range
$3.05 - $9.01
50D Avg
$5.17
200D Avg
$5.45
Market Cap
$236.50M
Avg Vol (3M)
$329.94K
Beta
1.51
Div Yield
-
ABEO Company Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CKPT | Checkpoint Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| CALA | Calithera Biosciences, Inc. |
| MREO | Mereo BioPharma Group plc |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PDSB | PDS Biotechnology Corporation |
| RGNX | REGENXBIO Inc. |
| ADAP | Adaptimmune Therapeutics plc |
| IVVD | Invivyd, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| FBIO | Fortress Biotech, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| CABA | Cabaletta Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ATHA | Athira Pharma, Inc. |
| AFMD | Affimed N.V. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| LPTX | Leap Therapeutics, Inc. |
| PIRS | Pieris Pharmaceuticals, Inc. |